Logo do repositório
 
Publicação

Chitosan and hyaluronic acid nanoparticles as vehicles of epoetin beta for subconjunctival ocular delivery

2022-02-18Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSilva, Beatriz
dc.contributor.authorGonçalves, Lídia M.
dc.contributor.authorFerreira São Braz, Berta
dc.contributor.authorDelgado, Esmeralda
dc.date.accessioned2022-04-27T10:15:27Z
dc.date.available2022-04-27T10:15:27Z
dc.date.issued2022-02-18
dc.descriptionResearch Areas: Pharmacology & Pharmacypt_PT
dc.description.abstractNeuroprotection in glaucoma using epoetin beta (EPOβ) has yielded promising results. Our team has developed chitosan-hyaluronic acid nanoparticles (CS/HA) designed to carry EPOβ into the ocular globe, improving the drug’s mucoadhesion and retention time on the ocular surface to increase its bioavailability. In the present in vivo study, we explored the possibility of delivering EPOβ to the eye through subconjunctival administration of chitosan-hyaluronic acid-EPOβ (CS/HA-EPOβ) nanoparticles. Healthy Wistar Hannover rats (n = 21) were split into 7 groups and underwent complete ophthalmological examinations, including electroretinography and microhematocrit evaluations before and after the subconjunctival administrations. CS/HA-EPOβ nanoparticles were administered to the right eye (OD), and the contralateral eye (OS) served as control. At selected timepoints, animals from each group (n = 3) were euthanized, and both eyes were enucleated for histological evaluation (immunofluorescence and HE). No adverse ocular signs, no changes in the microhematocrits (≈45%), and no deviations in the electroretinographies in both photopic and scotopic exams were observed after the administrations (p < 0.05). Intraocular pressure remained in the physiological range during the assays (11–22 mmHg). EPOβ was detected in the retina by immunofluorescence 12 h after the subconjunctival administration and remained detectable until day 21. We concluded that CS/HA nanoparticles could efficiently deliver EPOβ into the retina, and this alternative was considered biologically safe. This nanoformulation could be a promising tool for treating retinopathies, namely optic nerve degeneration associated with glaucoma.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSilva B, Gonçalves LM, Braz BS, Delgado E. 2022. Chitosan and hyaluronic acid nanoparticles as vehicles of epoetin beta for subconjunctival ocular delivery. Marine Drugs, 20(2):151. Doi 10.3390/md20020151pt_PT
dc.identifier.doi10.3390/md20020151pt_PT
dc.identifier.eissn1660-3397
dc.identifier.urihttp://hdl.handle.net/10400.5/24172
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationCEECIND/03143/2017pt_PT
dc.relationResearch Institute for Medicines
dc.relationCentre for Interdisciplinary Research in Animal Health
dc.relationRetinal erythropoietin distribution and neuroprotective effect in a nanoparticulate drug delivery system after subconjunctival and topical adminstration in an animal glaucoma model
dc.relation.publisherversionhttps://www.mdpi.com/1660-3397/20/2/151pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectNanoparticlespt_PT
dc.subjectMucoadhesionpt_PT
dc.subjectChitosanpt_PT
dc.subjectHyaluronic acidpt_PT
dc.subjectErythropoietinpt_PT
dc.subjectEpoetin betapt_PT
dc.subjectOcular deliverypt_PT
dc.titleChitosan and hyaluronic acid nanoparticles as vehicles of epoetin beta for subconjunctival ocular deliverypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleResearch Institute for Medicines
oaire.awardTitleCentre for Interdisciplinary Research in Animal Health
oaire.awardTitleRetinal erythropoietin distribution and neuroprotective effect in a nanoparticulate drug delivery system after subconjunctival and topical adminstration in an animal glaucoma model
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04138%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F00276%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F130476%2F2017/PT
oaire.citation.conferencePlaceBasel, Switzerlandpt_PT
oaire.citation.titleMarine Drugspt_PT
oaire.citation.volume20(2)pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
person.familyNameFernandes Ferreira São Braz
person.familyNameDelgado
person.givenNameBerta Maria
person.givenNameEsmeralda
person.identifierD-2518-2010
person.identifier.ciencia-idB11B-C3C7-3ADF
person.identifier.ciencia-id8D1E-61D6-0F40
person.identifier.orcid0000-0003-2688-0459
person.identifier.orcid0000-0001-9383-1310
person.identifier.scopus-author-id56008623000
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicatione50e9673-4f20-4b11-ae92-4d10e5c1ec80
relation.isAuthorOfPublication2be91d41-92eb-4d63-9713-140cce3a1004
relation.isAuthorOfPublication.latestForDiscoverye50e9673-4f20-4b11-ae92-4d10e5c1ec80
relation.isProjectOfPublicationbb00962c-ed82-4d7a-bc37-61df49767d93
relation.isProjectOfPublication8563a044-0c86-49a8-a275-8b1bb62cc0d8
relation.isProjectOfPublication0d64307f-85ff-4c0c-ab28-d0de1eedb6c3
relation.isProjectOfPublication.latestForDiscovery0d64307f-85ff-4c0c-ab28-d0de1eedb6c3

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Chitosan and Hyaluronic Acid Nanoparticles as Vehicles of Epoetin Beta for Subconjunctival Ocular Delivery.pdf
Tamanho:
50.24 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CIISA - Artigos em revistas internacionais